Caspase polymorphisms and genetic susceptibility to multiple myeloma

Howard D. Hosgood, Dalsu Baris, Yawei Zhang, Yong Zhu, Tongzhang Zheng, Meredith Yeager, Robert Welch, Shelia Zahm, Stephen Chanock, Nathaniel Rothman, Qing Lan

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Multiple myeloma is a haematological malignency, characterized by clonal expansion of plasma cells. However, little is known about the cause of multiple myeloma. Cancer cells must avoid apoptosis to ensure unregulated tumour formation and growth. The highly conserved caspase cascade is essential to the regulation of the apoptotic pathway. To examine if five single nucleotide polymorphisms (SNPs) in four caspase genes [CASP3 Ex8-280 C > A (rs6948), CASP3 Ex8 + 567 T > C (rs1049216), CASP8 Ex14-271 A > T (rs13113), CASP9 Ex5 + 32 G > A (rs1052576), CASP10 Ex3-171 A > G (rs39001150)] alter multiple myeloma risk, we conducted a population-based case-control study of women (128 cases; 516 controls) in Connecticut. Compared to individuals with the TT genotype of CASP3 Ex8 + 567 T > C, subjects with the CC genotype had a five-fold decreased risk of multiple myeloma (odds ratio (OR)CC=0.2, 95% confidence interval (CI) - 0.0-1.0). Further, individuals with the AG and AA genotypes of CASP9 Ex5+32 G > A also experienced a decreased risk of multiple myeloma (ORAG=0.8, 95% CI - 0.5-1.3; ORAA=0.5, 95% CI - 0.3-0.9; p-trend = 0.02). While no previous study has evaluated the association between caspase genes and multiple myeloma, studies have found associations with lung, breast, esophageal, gastric, colorectal and cervical cancers. Our parallel study of non-Hodgkin lymphoma, which utilized the same controls, found strong evidence that caspase genes play a key role in lymphogenesis. The protective associations observed in two key caspase genes suggest that genetic variation in CASP genes may play an important role in the aetiology of multiple myeloma.

Original languageEnglish (US)
Pages (from-to)148-151
Number of pages4
JournalHematological Oncology
Volume26
Issue number3
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Genetic Predisposition to Disease
Caspases
Multiple Myeloma
Caspase 3
Genes
Genotype
Confidence Intervals
Esophageal Neoplasms
Plasma Cells
Uterine Cervical Neoplasms
Non-Hodgkin's Lymphoma
Stomach Neoplasms
Single Nucleotide Polymorphism
Case-Control Studies
Colorectal Neoplasms
Lung Neoplasms
Neoplasms
Odds Ratio
Apoptosis
Breast Neoplasms

Keywords

  • Caspase
  • Multiple myeloma
  • Polymorphism
  • Risk factors
  • Snp
  • Variant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Hosgood, H. D., Baris, D., Zhang, Y., Zhu, Y., Zheng, T., Yeager, M., ... Lan, Q. (2008). Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematological Oncology, 26(3), 148-151. https://doi.org/10.1002/hon.852

Caspase polymorphisms and genetic susceptibility to multiple myeloma. / Hosgood, Howard D.; Baris, Dalsu; Zhang, Yawei; Zhu, Yong; Zheng, Tongzhang; Yeager, Meredith; Welch, Robert; Zahm, Shelia; Chanock, Stephen; Rothman, Nathaniel; Lan, Qing.

In: Hematological Oncology, Vol. 26, No. 3, 2008, p. 148-151.

Research output: Contribution to journalArticle

Hosgood, HD, Baris, D, Zhang, Y, Zhu, Y, Zheng, T, Yeager, M, Welch, R, Zahm, S, Chanock, S, Rothman, N & Lan, Q 2008, 'Caspase polymorphisms and genetic susceptibility to multiple myeloma', Hematological Oncology, vol. 26, no. 3, pp. 148-151. https://doi.org/10.1002/hon.852
Hosgood, Howard D. ; Baris, Dalsu ; Zhang, Yawei ; Zhu, Yong ; Zheng, Tongzhang ; Yeager, Meredith ; Welch, Robert ; Zahm, Shelia ; Chanock, Stephen ; Rothman, Nathaniel ; Lan, Qing. / Caspase polymorphisms and genetic susceptibility to multiple myeloma. In: Hematological Oncology. 2008 ; Vol. 26, No. 3. pp. 148-151.
@article{a21ec042eca747f9941f755f28f4d605,
title = "Caspase polymorphisms and genetic susceptibility to multiple myeloma",
abstract = "Multiple myeloma is a haematological malignency, characterized by clonal expansion of plasma cells. However, little is known about the cause of multiple myeloma. Cancer cells must avoid apoptosis to ensure unregulated tumour formation and growth. The highly conserved caspase cascade is essential to the regulation of the apoptotic pathway. To examine if five single nucleotide polymorphisms (SNPs) in four caspase genes [CASP3 Ex8-280 C > A (rs6948), CASP3 Ex8 + 567 T > C (rs1049216), CASP8 Ex14-271 A > T (rs13113), CASP9 Ex5 + 32 G > A (rs1052576), CASP10 Ex3-171 A > G (rs39001150)] alter multiple myeloma risk, we conducted a population-based case-control study of women (128 cases; 516 controls) in Connecticut. Compared to individuals with the TT genotype of CASP3 Ex8 + 567 T > C, subjects with the CC genotype had a five-fold decreased risk of multiple myeloma (odds ratio (OR)CC=0.2, 95{\%} confidence interval (CI) - 0.0-1.0). Further, individuals with the AG and AA genotypes of CASP9 Ex5+32 G > A also experienced a decreased risk of multiple myeloma (ORAG=0.8, 95{\%} CI - 0.5-1.3; ORAA=0.5, 95{\%} CI - 0.3-0.9; p-trend = 0.02). While no previous study has evaluated the association between caspase genes and multiple myeloma, studies have found associations with lung, breast, esophageal, gastric, colorectal and cervical cancers. Our parallel study of non-Hodgkin lymphoma, which utilized the same controls, found strong evidence that caspase genes play a key role in lymphogenesis. The protective associations observed in two key caspase genes suggest that genetic variation in CASP genes may play an important role in the aetiology of multiple myeloma.",
keywords = "Caspase, Multiple myeloma, Polymorphism, Risk factors, Snp, Variant",
author = "Hosgood, {Howard D.} and Dalsu Baris and Yawei Zhang and Yong Zhu and Tongzhang Zheng and Meredith Yeager and Robert Welch and Shelia Zahm and Stephen Chanock and Nathaniel Rothman and Qing Lan",
year = "2008",
doi = "10.1002/hon.852",
language = "English (US)",
volume = "26",
pages = "148--151",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Caspase polymorphisms and genetic susceptibility to multiple myeloma

AU - Hosgood, Howard D.

AU - Baris, Dalsu

AU - Zhang, Yawei

AU - Zhu, Yong

AU - Zheng, Tongzhang

AU - Yeager, Meredith

AU - Welch, Robert

AU - Zahm, Shelia

AU - Chanock, Stephen

AU - Rothman, Nathaniel

AU - Lan, Qing

PY - 2008

Y1 - 2008

N2 - Multiple myeloma is a haematological malignency, characterized by clonal expansion of plasma cells. However, little is known about the cause of multiple myeloma. Cancer cells must avoid apoptosis to ensure unregulated tumour formation and growth. The highly conserved caspase cascade is essential to the regulation of the apoptotic pathway. To examine if five single nucleotide polymorphisms (SNPs) in four caspase genes [CASP3 Ex8-280 C > A (rs6948), CASP3 Ex8 + 567 T > C (rs1049216), CASP8 Ex14-271 A > T (rs13113), CASP9 Ex5 + 32 G > A (rs1052576), CASP10 Ex3-171 A > G (rs39001150)] alter multiple myeloma risk, we conducted a population-based case-control study of women (128 cases; 516 controls) in Connecticut. Compared to individuals with the TT genotype of CASP3 Ex8 + 567 T > C, subjects with the CC genotype had a five-fold decreased risk of multiple myeloma (odds ratio (OR)CC=0.2, 95% confidence interval (CI) - 0.0-1.0). Further, individuals with the AG and AA genotypes of CASP9 Ex5+32 G > A also experienced a decreased risk of multiple myeloma (ORAG=0.8, 95% CI - 0.5-1.3; ORAA=0.5, 95% CI - 0.3-0.9; p-trend = 0.02). While no previous study has evaluated the association between caspase genes and multiple myeloma, studies have found associations with lung, breast, esophageal, gastric, colorectal and cervical cancers. Our parallel study of non-Hodgkin lymphoma, which utilized the same controls, found strong evidence that caspase genes play a key role in lymphogenesis. The protective associations observed in two key caspase genes suggest that genetic variation in CASP genes may play an important role in the aetiology of multiple myeloma.

AB - Multiple myeloma is a haematological malignency, characterized by clonal expansion of plasma cells. However, little is known about the cause of multiple myeloma. Cancer cells must avoid apoptosis to ensure unregulated tumour formation and growth. The highly conserved caspase cascade is essential to the regulation of the apoptotic pathway. To examine if five single nucleotide polymorphisms (SNPs) in four caspase genes [CASP3 Ex8-280 C > A (rs6948), CASP3 Ex8 + 567 T > C (rs1049216), CASP8 Ex14-271 A > T (rs13113), CASP9 Ex5 + 32 G > A (rs1052576), CASP10 Ex3-171 A > G (rs39001150)] alter multiple myeloma risk, we conducted a population-based case-control study of women (128 cases; 516 controls) in Connecticut. Compared to individuals with the TT genotype of CASP3 Ex8 + 567 T > C, subjects with the CC genotype had a five-fold decreased risk of multiple myeloma (odds ratio (OR)CC=0.2, 95% confidence interval (CI) - 0.0-1.0). Further, individuals with the AG and AA genotypes of CASP9 Ex5+32 G > A also experienced a decreased risk of multiple myeloma (ORAG=0.8, 95% CI - 0.5-1.3; ORAA=0.5, 95% CI - 0.3-0.9; p-trend = 0.02). While no previous study has evaluated the association between caspase genes and multiple myeloma, studies have found associations with lung, breast, esophageal, gastric, colorectal and cervical cancers. Our parallel study of non-Hodgkin lymphoma, which utilized the same controls, found strong evidence that caspase genes play a key role in lymphogenesis. The protective associations observed in two key caspase genes suggest that genetic variation in CASP genes may play an important role in the aetiology of multiple myeloma.

KW - Caspase

KW - Multiple myeloma

KW - Polymorphism

KW - Risk factors

KW - Snp

KW - Variant

UR - http://www.scopus.com/inward/record.url?scp=55249115329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249115329&partnerID=8YFLogxK

U2 - 10.1002/hon.852

DO - 10.1002/hon.852

M3 - Article

VL - 26

SP - 148

EP - 151

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3

ER -